New insights in the treatment of radioiodine refractory differentiated thyroid carcinomas: to lenvatinib and beyond.
Wang E, Karedan T, Perez CA.
Anticancer Drugs · review; journal article · DOI 10.1097/cad.0000000000000247 PUBLICATION REGISTRY
Go to research.
Publikationsdata från Europe PMC och PubMed. Följ källhänvisningar från ämnesregistret till originalpublikationerna.
Publikationer som ChEBI hänvisar till för lenvatinib. Visa hela publikationsregistret
A publication hit is not a conclusion. Publikationslistan visar bibliografiska uppgifter. Eventuella forskningsutdrag visas separat med originalunderlag. En källhänvisning visar inte i sig effekt, dosering eller säkerhet.
Publications in the selection
14 hitsUpdate on Cardiovascular Safety of Tyrosine Kinase Inhibitors: With a Special Focus on QT Interval, Left Ventricular Dysfunction and Overall Risk/Benefit.
Shah RR, Morganroth J.
Drug Saf · review; journal article · DOI 10.1007/s40264-015-0300-1A validated LC-MS/MS method of total and unbound lenvatinib quantification in human serum for protein binding studies by equilibrium dialysis.
Mano Y, Kusano K.
J Pharm Biomed Anal · validation study; journal article · DOI 10.1016/j.jpba.2015.05.008A phase 2 trial of lenvatinib (E7080) in advanced, progressive, radioiodine-refractory, differentiated thyroid cancer: A clinical outcomes and biomarker assessment.
Cabanillas ME, Schlumberger M, Jarzab B, Martins RG, Pacini F, Robinson B, McCaffrey JC, Shah MH, Bodenner DL, Topliss D, Andresen C, O'Brien JP, Ren M, Funahashi Y, Allison R, Elisei R, Newbold K, Licitra LF, Sherman SI, Ball DW.
Cancer · clinical trial, phase ii; research support, non-u.s. gov't; research-article; journal article · DOI 10.1002/cncr.29395Lenvatinib: first global approval.
Scott LJ.
Drugs · review; journal article · DOI 10.1007/s40265-015-0383-0Pharmaceutical approval update.
Gohil K.
P T · other; journal articleLenvatinib approved for certain thyroid cancers.
Författaruppgift saknas
Cancer Discov · news · DOI 10.1158/2159-8290.cd-nb2015-029Multitargeting strategy using lenvatinib and golvatinib: maximizing anti-angiogenesis activity in a preclinical cancer model.
Nakazawa Y, Kawano S, Matsui J, Funahashi Y, Tohyama O, Muto H, Nakagawa T, Matsushima T.
Cancer Sci · research support, non-u.s. gov't; research-article; journal article · DOI 10.1111/cas.12581Progress in Discovery of KIF5B-RET Kinase Inhibitors for the Treatment of Non-Small-Cell Lung Cancer.
Song M.
J Med Chem · journal article · DOI 10.1021/jm501464cA randomized, three-treatment, three-period, six-sequence-crossover, single-center, bioequivalence study to evaluate the impact of different 10-mg crystalline forms on the pharmacokinetics of lenvatinib in healthy volunteers.
Lee L, D'Angelo P, Verbel D, Martinez G, Aluri J, Brimhall D.
Int J Clin Pharmacol Ther · research support, non-u.s. gov't; randomized controlled trial; journal article · DOI 10.5414/cp202216Lenvatinib versus placebo in radioiodine-refractory thyroid cancer.
Schlumberger M, Tahara M, Wirth LJ, Robinson B, Brose MS, Elisei R, Habra MA, Newbold K, Shah MH, Hoff AO, Gianoukakis AG, Kiyota N, Taylor MH, Kim SB, Krzyzanowska MK, Dutcus CE, de las Heras B, Zhu J, Sherman SI.
N Engl J Med · clinical trial, phase iii; comparative study; research support, non-u.s. gov't; multicenter study; randomized controlled trial; journal article · DOI 10.1056/nejmoa1406470Differentiated thyroid cancer: focus on emerging treatments for radioactive iodine-refractory patients.
Gruber JJ, Colevas AD.
Oncologist · review-article; review; journal article · DOI 10.1634/theoncologist.2014-0313Distinct binding mode of multikinase inhibitor lenvatinib revealed by biochemical characterization.
Okamoto K, Ikemori-Kawada M, Jestel A, von König K, Funahashi Y, Matsushima T, Tsuruoka A, Inoue A, Matsui J.
ACS Med Chem Lett · rapid-communication; journal article · DOI 10.1021/ml500394mThe evolving field of kinase inhibitors in thyroid cancer.
Marotta V, Sciammarella C, Vitale M, Colao A, Faggiano A.
Crit Rev Oncol Hematol · review; journal article · DOI 10.1016/j.critrevonc.2014.08.007